Valacyclovir Monotherapy in Pain Management of Acute Periapical Abscesses After Emergency Chamber Opening

Sponsor
Dow University of Health Sciences
Study ID
NCT06344195
Phase
PHASE4
Status
Unknown

Conditions

  • Acute Apical Abscess

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Accepted

Interventions

  • Valacyclovir 500 mg — DRUG
    Valtrex 2g immediate dose followed by 500mg 2 times daily for 3 days along with the analgesic (SOS, if needed) for 6 days
  • Naproxen Sodium 550mg — DRUG
    550mg (as needed, SOS) for 6 days

Study Details

This study is aimed to evaluate the efficacy of valacyclovir in reducing postoperative pain following emergency chamber opening for acute apical abscess . There will be 82 participants, (41 in each group) Group A will receive Valacyclovir Group B will receive standard treatment i.e. Naproxen Sodium. Pain level will be assessed by using Numeric rating scale for 6 days

Key Dates

Start date
Mar 27, 2024
Status verified
Apr 2024
Primary completion
Apr 30, 2024
Completion
May 31, 2024

Study Design

Enrollment
82 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Valacyclovir Group
    participants will be given prescription of valacyclovir (2g immediate dose followed by 500mg 2 times daily for 3 days) along with the analgesic, Naproxen sodium, 550mg (SOS, if needed) Data will be recorded daily for 6 days
  • Active Comparator: Control Group
    this is control group and is prescribed with analgesic, Naproxen sodium, 550mg (SOS, if needed) only

Primary Outcome Measure

Changes in pain score using Numeric Rating Scale (NRS) [ Time Frame: 6 days ]

Central Contacts

Related Studies